Raziel Therapeutics Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 11

Raziel Therapeutics General Information

Description

Manufacturer of injectable drugs designed to decrease submental fat and fat disorders. The company offers a single injection treatment into subcutaneous fat that causes immediate fat cell death at the injection site, enabling healthcare professionals to provide patients with a significant treatment fat reduction for long periods without any invasive procedures.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 10 Prof. Menachem Plaut Street
  • Rehovot 7670621
  • Israel
+972
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • 10 Prof. Menachem Plaut Street
  • Rehovot 7670621
  • Israel
+972

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Raziel Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 01-Oct-2025 Completed Clinical Trials - Phase 3
6. Secondary Transaction - Private 20-Mar-2020 Completed Clinical Trials - Phase 3
5. Later Stage VC (Series C) 18-Dec-2019 Completed Clinical Trials - Phase 3
4. Early Stage VC (Series A) 25-Feb-2016 Completed Clinical Trials - Phase 1
3. Early Stage VC 10-Jul-2015 Completed Clinical Trials - Phase 3
2. Seed Round 01-Dec-2014 $600K $1.19M Completed Clinical Trials - Phase 1
1. Early Stage VC 03-Dec-2012 $589K $589K Completed Clinical Trials - Phase 1
To view Raziel Therapeutics’s complete valuation and funding history, request access »

Raziel Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preferred C
Preferred B2
Preferred B1
Preferred A2
Preferred A1 25,000 $16.67 $16.67 1x $16.67 2.61%
Preferred A 75,000 $7.59 $7.59 1x $7.59 3.91%
To view Raziel Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Raziel Therapeutics Patents

Raziel Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023378681-A1 Crystalline carbazole derivative and methods of making thereof Pending 07-Nov-2022
EP-4615443-A1 Crystalline carbazole derivative and methods of making thereof Pending 07-Nov-2022
EP-4615443-A4 Crystalline carbazole derivative and methods of making thereof Pending 07-Nov-2022
WO-2024100533-A1 Crystalline carbazole derivative and methods of making thereof Inactive 07-Nov-2022
AU-2022320006-A1 Compositions and methods for treating lipoma pain Inactive 28-Jul-2021 A61K31/403
To view Raziel Therapeutics’s complete patent history, request access »

Raziel Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Raziel Therapeutics Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Yissum Accelerator/Incubator Minority
Catalyst Investments PE/Buyout Minority
China Everbright Asset Manager Minority
Peregrine Ventures Venture Capital Minority
Wille Finance Family Office Minority
You’re viewing 5 of 11 investors. Get the full list »

Raziel Therapeutics FAQs

  • When was Raziel Therapeutics founded?

    Raziel Therapeutics was founded in 2012.

  • Where is Raziel Therapeutics headquartered?

    Raziel Therapeutics is headquartered in Rehovot, Israel.

  • What is the size of Raziel Therapeutics?

    Raziel Therapeutics has 7 total employees.

  • What industry is Raziel Therapeutics in?

    Raziel Therapeutics’s primary industry is Drug Discovery.

  • Is Raziel Therapeutics a private or public company?

    Raziel Therapeutics is a Private company.

  • What is Raziel Therapeutics’s current revenue?

    The current revenue for Raziel Therapeutics is .

  • How much funding has Raziel Therapeutics raised over time?

    Raziel Therapeutics has raised $29.3M.

  • Who are Raziel Therapeutics’s investors?

    Yissum, Catalyst Investments, China Everbright, Peregrine Ventures, and Wille Finance are 5 of 11 investors who have invested in Raziel Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process